Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease
Background and objectives: We assessed the evolution of perianal lesions after switching intravenous (IV) to subcutaneous (SC) infliximab in patients with Crohn’s disease (CD). Design: Subgroup analysis of REMSWITCH studies. Methods: We described the clinical and MRI outcomes of patients with a prio...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-03-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251326471 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|